CoChat

The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis

Open access
Osinubi, O., Grainge, M.J., Hong, L., Ahmed, A., Batchelor, J.M., Grindlay, D., Thompson, A.R., Ratib, S. · 2018 · British Journal of Dermatology
Cited by 119

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Summary: Background: Vitiligo is a chronic disorder causing skin depigmentation with global prevalence varying from 0·2% to 1·8%. U.K. guidelines recommend assessment of psychological state during clinical evaluation of vitiligo. However, the prevalence of psychological comorbidity in people with vitiligo has not been described. Objectives: To establish the prevalence of psychological symptoms or disorders in people with vitiligo and describe the outcome measures used. Methods: We performed a comprehensive search of MEDLINE, Embase, CINAHL and PsycINFO to identify observational studies assessing the prevalence of psychological symptoms or disorders (December 2016). DerSimonian and Lard random-effects models were used to estimate the overall pooled prevalence. Results: We identified 29 studies with 2530 people with vitiligo. Most studies included a measure of either depression (n =25) or anxiety (n =13). The commonest tools were the Hospital Anxiety and Depression Scale and the Centre for Epidemiology Studies Depression Scale. Ten studies provided information on 13 other psychological outcomes. Pooled prevalence using depression-specific and anxiety-specific questionnaires was 0·29 [95% confidence interval (CI) 0·21–0·38] and 0·33 (95% CI 0·18–0·49), respectively. Prevalence was lower for clinically diagnosed depression (0·21, 95% CI 0·15–0·28) and anxiety (0·15, 95% CI 0·06–0·24). When nonspecific tools were used the prevalence remained similar for depression (0·27, 95% CI 0·08–0·46) but increased for anxiety (0·46, 95% CI 0·39–0·52). High heterogeneity was observed. Conclusions: A range of psychological outcomes are common in people with vitiligo. The prevalence of anxiety was influenced by type of screening tool, suggesting the need for validation of psychological outcome screening tools in the field of dermatology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjd.16049

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 50

  1. Ezzedine, 2015, Vitiligo, Lancet, 386, 74, 10.1016/S0140-6736(14)60763-7 · DOI · Paper page
  2. Gawkrodger, 2008, Guidelines for the diagnosis and management of vitiligo, Br J Dermatol, 159, 1051, 10.1111/j.1365-2133.2008.08881.x · DOI · Paper page
  3. Zhang, 2016, The prevalence of vitiligo: a meta-analysis, PLOS ONE, 11, e163806
  4. Sandoval-Cruz, 2011, Immunopathogenesis of vitiligo, Autoimmun Rev, 10, 762, 10.1016/j.autrev.2011.02.004 · DOI · Paper page
  5. Richmond, 2013, Innate immune mechanisms in vitiligo: danger from within, Curr Opin Immunol, 25, 676, 10.1016/j.coi.2013.10.010 · DOI · Paper page
  6. Gey, 2013, Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms, Br J Dermatol, 168, 756, 10.1111/bjd.12166 · DOI
  7. Whitton, 2015, Interventions for vitiligo, Cochrane Database Syst Rev, 2, CD003263
  8. Lilly, 2013, Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL), J Am Acad Dermatol, 69, e11, 10.1016/j.jaad.2012.01.038 · DOI · Paper page
  9. Jayaprakasam, 2002, Comparison of assessments of severity and quality of life in cutaneous disease, Clin Exp Dermatol, 27, 306, 10.1046/j.1365-2230.2002.01025.x · doi:10.1046/j.1365-2230.2002.01025.x
  10. Harlow, 2000, Impaired quality of life of adults with skin disease in primary care, Br J Dermatol, 143, 979, 10.1046/j.1365-2133.2000.03830.x · DOI
  11. Halioua, 2000, Quality of life in dermatology, Int J Dermatol, 39, 801, 10.1046/j.1365-4362.2000.00793.x · DOI
  12. Kent, 1996, Psychologic effects of vitiligo: a critical incident analysis, J Am Acad Dermatol, 35, 895, 10.1016/S0190-9622(96)90112-7 · DOI · Paper page
  13. Hann, 2000, Vitiligo, 10.1002/9780470760116 · DOI
  14. Lai, 2017, Vitiligo and depression: a systematic review and meta-analysis of observational studies, Br J Dermatol, 177, 708, 10.1111/bjd.15199 · DOI · Paper page
  15. Eleftheriadou, 2011, Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership, Br J Dermatol, 164, 530
  16. Morrison, 2017, Quality of life in people with vitiligo: a systematic review and meta-analysis, Br J Dermatol, 177, e338, 10.1111/bjd.15933 · DOI · Paper page
  17. Moher, 2009, Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement, PLOS Med, 6, e1000097, 10.1371/journal.pmed.1000097 · DOI · Paper page
  18. Ottawa Hospital Research Institute, The Newcastle Ottawa Scale for assessing quality of nonrandomised studies in meta-analysis
  19. National Heart, Lung and Blood Institute, Quality assessment of case-control studies
  20. National Heart, Lung and Blood Institute, Quality assessment tool for observational cohort and cross-sectional studies
  21. DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  22. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  23. Porter, 1987, Response to cosmetic disfigurement: patients with vitiligo, Cutis, 39, 493
  24. Delfino, 1988, Personality profiles in patients with alopecia areata, Annal Ital Dermatol, 42, 271
  25. Vilella, 1998, Vitiligo: psychological aspects, Rev Hosp Psiquiatr La Habana, 29, 463
  26. Sharma, 2001, Psychiatric morbidity in psoriasis and vitiligo: a comparative study, J Dermatol, 28, 419, 10.1111/j.1346-8138.2001.tb00003.x · DOI · Paper page
  27. Mattoo, 2002, Psychiatric morbidity in vitiligo: prevalence and correlates in India, J Eur Acad Dermatol Venereol, 16, 573, 10.1046/j.1468-3083.2002.00590.x · DOI · Paper page
  28. Sampogna, 2004, Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions, Psychosom Med, 66, 620, 10.1097/01.psy.0000132869.96872.b2 · DOI
  29. Mechri, 2006, Psychiatric morbidity and quality of life in vitiligo: a case controlled study, Tunis Med, 84, 632
  30. Ahmed, 2007, Frequency and pattern of psychiatric disorders in patients with vitiligo, J Ayub Med Coll Abbottabad, 19, 19
  31. Arýcan, 2008, Clinical characteristics in 113 Turkish vitiligo patients, Acta Dermatoven Alp Pannonica Adrita, 17, 129
  32. Saleh, 2008, Comparative study of psychiatric morbidity and QoL in psoriasis, vitiligo and alopecia, Egypt Dermatol Online J, 4, 1
  33. Sampogna, 2008, Identification of categories at risk for high quality of life impairment in patients with vitiligo, Br J Dermatol, 159, 351, 10.1111/j.1365-2133.2008.08678.x · DOI
  34. Nogueira, 2009, [Vitiligo and Emotions], An Bras Dermatol, 84, 41, 10.1590/S0365-05962009000100006 · DOI
  35. Osman, 2009, The psychological impact of vitiligo in adult Sudanese patients, Afr J Psych, 12, 284, 10.4314/ajpsy.v12i4.49045 · DOI
  36. AlGhamdi, 2010, Beliefs and perceptions of Arab vitiligo patients regarding their condition, Int J Dermatol, 49, 1141, 10.1111/j.1365-4632.2010.04514.x · DOI
  37. Bashir, 2010, Depression in adult dermatology outpatients, J Coll Physicians Surg Pak, 20, 811
  38. Choi, 2010, Quality of life and psychological adaptation of Korean adolescents with vitiligo, J Eur Acad Dermatol Venereol, 24, 524, 10.1111/j.1468-3083.2009.03452.x · DOI · Paper page
  39. Balaban, 2011, Psychiatric morbidity in patients with vitiligo, Dusunen Adam, 24, 306, 10.5350/DAJPN2011240406 · DOI
  40. Chan, 2011, Investigating factors associated with depression of vitiligo patients in Singapore, J Clin Nurs, 21, 1614, 10.1111/j.1365-2702.2011.03777.x · DOI
  41. Yamamoto, 2011, Application of a two-question screening instrument to detect depressive symptoms in patients with vitiligo: a pilot study, J Am Acad Dermatol, 64, e69, 10.1016/j.jaad.2010.05.031 · DOI
  42. Karelson, 2013, Quality of life and emotional state in vitiligo in an Estonian sample: Comparison with psoriasis and healthy controls, Acta Dermato Venereologica., 93, 446, 10.2340/00015555-1520 · DOI · Paper page
  43. Chan, 2013, Investigating factors associated with quality of life of vitiligo patients in Singapore, Int J Nurs Pract, 19, 3, 10.1111/ijn.12179 · DOI
  44. Ajose, 2013, Quantification and comparison of psychiatric distress in African patients with albinism and vitiligo: a 5-year prospective study, J Eur Acad Dermatol Venereol, 28, 925, 10.1111/jdv.12216 · DOI
  45. Ramakrishna, 2014, Psychiatric morbidity and quality of life in vitiligo patients, Indian J Psychol Med, 36, 302, 10.4103/0253-7176.135385 · DOI
  46. Alshahwan, 2015, The prevalence of anxiety and depression in Arab dermatology patients, J Cutan Med Surg, 19, 297, 10.2310/7750.2014.14110 · DOI
  47. Saleki, 2015, Prevalence and frequency of depression in patients with vitiligo, Int J Curr Microbiol Appl Sci, 4, 437
  48. Karia, 2015, Psychiatric morbidity and quality of life in skin diseases: a comparison of alopecia areata and psoriasis, Ind Psychiatry J, 24, 125, 10.4103/0972-6748.181724 · DOI
  49. Tsintsadze, 2015, Psychosomatic aspects in patients with dermatologic diseases, Georgia Medic News, 243, 70
  50. Elbuluk, 2017, Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients, Dermatol Clin, 35, 117, 10.1016/j.det.2016.11.002 · DOI

Cited by

See all 119

Metadata

Authors
Osinubi, O., Grainge, M. J., Hong, L., Ahmed, A., Batchelor, J. M., Grindlay, D., Thompson, A. R., & Ratib, S.
Venue
British Journal of Dermatology
Published
2018-04-01
Volume
178
Issue
4
Pages
863-878
ISSN
  • 0007-0963 (ISSN-L)
  • 1365-2133
OpenAlex
W2762693917
Cited by
119
References
5
FWCI
0.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.